Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Raman Self-Tracking Copper Metal-Organic Framework-Based Nanoplatform for Cuproptosis Cancer Therapy.

Created on 04 Oct 2026

Authors

Yujie Duan, Ying Bao, Ziwen Gao, Xidong He, Xinming Liu, Hao Wang, Chunsheng Xiao, Xuesi Chen

Published in

Angewandte Chemie (International ed. in English). Pages e9809366. Oct 04, 2026. Epub Oct 04, 2026.

Abstract

Cuproptosis represents a promising strategy for cancer therapy, yet its clinical translation is hampered by unexpected deactivation and off-target toxicity of copper ions during their delivery to tumors. We developed a copper metal-organic framework-based nanoplatform (CuF) with H2O2 responsiveness and Raman self-tracking capability for cuproptosis-mediated antitumor therapy. CuF was prepared by coordinating Cu2+ with an alkyne-bearing ligand, followed by PEGylation and incorporation of an iron-based catalyst. CuF undergoes catalyst-mediated oxidative cleavage of alkynyl bonds under tumor-associated elevated H2O2 levels, causing CuF degradation and Cu2+ release. Released Cu2+ causes copper overload in tumor cells, thereby inducing potent cuproptosis. Meanwhile, the resultant aldehydes and acids generated by the oxidative cleavage of alkynes can further synergistically potentiate cuproptosis. Consequently, CuF demonstrated high antitumor efficacy in a 4T1 tumor-bearing mouse model (with a tumor inhibition rate of 91%). Moreover, alkynes in the metal-organic framework (MOF) backbone provided an intrinsically enhanced Raman signal, enabling label-free self-tracking of CuF distribution and degradation in cells and tissue sections through Raman imaging. Overall, this work not only provides a new paradigm for cuproptosis-based anticancer agents, but also offers a versatile strategy for engineering H2O2 responsive materials and Raman imaging nanoplatforms.

PMID:
42829822
Bibliographic data and abstract were imported from PubMed on 04 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement